President Trump released his FY 2018 Budget Blueprint March 17, 2017, beginning a conversation with Congress on how to fund federal policies and programs. This budget outlines, at a high level, which policies and programs this Administration prioritizes, and it describes the kind of country this Administration wants to lead. […]
In comments submitted to the National Library of Medicine, AMIA said members envision a future where NLM leads the medical and research enterprise in demonstrating how real-world and “big” health data can be leveraged to develop new concepts of human disease, design novel therapies, and train future clinicians and researchers.
In comments submitted to the Centers for Disease Control and Prevention, AMIA recommended CDC pursue activities with the notion of CDS-as-a-Service as the conceptual goal. CDC must ensure that a coordinated strategy presents stakeholders with a unified vision for how public health CDS can be leveraged, AMIA said.
In comments submitted to PCORI, AMIA voiced strong support for its draft Data Sharing Policy for awardees. AMIA recommended that suggested that PCORI consider requiring a preliminary data sharing plan as part of award applications, and earmarking specified amounts of grant funding for data preparation and curation, among other recommendations.
In comments submitted to the NIH, AMIA called for change to its Data Sharing policy in order to ensure that research data can be systematically and strategically collected, managed and shared. Specifically, AMIA recommended that Data Sharing Plans be subject to peer-review and made scorable elements of applicable grants.
In comments submitted to the FDA, AMIA voiced supported for several aspects of MDUFA IV meant to enhance use of consensus standards; develop patient engagement strategies and improve the science of patient input; utilize real world evidence (RWE) to improve regulatory decision-making; and development of a policy framework for Digital […]
In comments submitted to the FDA, AMIA supported the use of real-world data and real-world evidence to support regulatory decision-making for medical devices.
In comments submitted to the FDA, AMIA said it supports FDA’s efforts to develop modern, flexible and adaptive regulatory approaches to the oversight of NGS-based tests as part of the Precision Medicine Initiative (PMI). This support notwithstanding, AMIA noted a lack of standards – for ontologies, metadata and other technical […]